Zobrazeno 101 - 110
of 668
pro vyhledávání: ''
Autor:
Merrill J. Egorin, Steven R. Tahan, Jo Ann Proper, Glenn J. Bubley, Bruce J. Dezube, Thomas Miller, Henry B. Koon, Liron Pantanowitz, David Masiello, Pamela Chatis, Brad Smith, Will Weeden, Katherine Crosby
Publikováno v:
Journal of Clinical Oncology. 23:982-989
Purpose Activation of the platelet-derived growth factor (PDGF) and c-kit receptors has been proposed as important in mediating the growth of AIDS-related Kaposi's sarcoma (KS). We investigated the response of KS to the PDGF receptor (PDGFR)/c-kit in
Autor:
Lisa Bomgaars, R. Klenke, J. R. Geyer, Jin-Hong Park, S. M. Blaney, J. Franklin, Naomi J. Winick, Gary V. Dahl, S. L. Berg
Publikováno v:
Journal of Clinical Oncology. 22:3916-3921
Purpose We performed a phase I trial of intrathecal (IT) liposomal cytarabine (DepoCyt; Enzon Pharmaceuticals, Piscataway, NJ and SkyePharma Inc, San Diego, CA) to determine the maximum-tolerated dose, the dose-limiting toxicities, and the plasma and
Autor:
Laurent Capelle, Hugues Duffau, Philippe Cornu, Antoine F. Carpentier, Jean-Marc Simon, Karima Mokhtari, Julie Lejeune, S. Taillibert, F. Laigle, Yannick Marie, Marc Sanson, Philippe Broët, Emmanuelle Crinière, Jean Yves Delattre, Khê Hoang-Xuan, Marc Polivka, Michèle Kujas
Publikováno v:
Journal of Clinical Oncology. 22:3133-3138
Purpose To determine the response rate of low-grade oligodendroglial tumors (LGOT) to temozolomide (TMZ) as initial treatment and to evaluate the predictive value of chromosome 1p deletion on the radiologic response. Patients and Methods Adult patien
Publikováno v:
Journal of Clinical Oncology. 22:2167-2171
Purpose The aim of this study was to evaluate response to therapy using posttherapy molecular imaging with [18F] fluorodeoxyglucose (FDG), and to compare the response with patient outcome. Patients and Methods This was a retrospective medical record
Autor:
David A. Taber, Christopher W. Ryan, Nancy B. Davis, Everett E. Vokes, Rafat Ansari, Nicholas J. Vogelzang, Christopher George, Walter M. Stadler
Publikováno v:
Journal of Clinical Oncology. 22:115-119
Purpose Determine response rate, time to disease progression, and toxicity of the proteasome inhibitor PS-341 in patients with stage IV renal cell cancer. Patients and Methods PS-341 1.5 mg/m2 was administered intravenously twice weekly for 2 weeks e
Publikováno v:
Journal of Clinical Oncology. 30:4451-4453
Given its identity as the first common malignancy with a molecular target, it is not surprising that breast cancer is the battleground for the many controversies that surround the use of multiparametric biomarker assays to guide cancer therapy. Histo
Publikováno v:
Journal of Clinical Oncology. 30:4285-4287
Positron emission tomography (PET) with [F]fluorodeoxyglucose (FDG) is not as well established for use in follicular lymphoma (FL) as it is for Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). The likely reason is that the clinical be
Autor:
Levi A. Garraway
Publikováno v:
Journal of Clinical Oncology. 30:2937-2939
Systematic tumor genomic profiling has the following two overarching objectives in clinical oncology: the matching of a cancer drug to a specific tumor genetic context and the identification of tumors for which use of a specific therapy would prove f
Publikováno v:
Journal of Clinical Oncology. 30:2812-2814
In recent years, there has been increasing evidence that a complex relationship may exist between diabetes, diabetes treatments, and cancer. An article by Chlebowski et al in Journal of Clinical Oncology reports the results of an exploration of these
Autor:
Burkhard Schmidt, Markus Schwaiger, Thomas M. Link, Christian Peschel, Volker Petersen, Leishia Tyndale-Hines, Wolfgang A. Weber
Publikováno v:
Journal of Clinical Oncology. 21:2651-2657
Purpose: To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods: